Ratings by Baird (Colleen Kusy)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | Climb Bio | CLYM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2026 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2026 | Iovanace Biotherapeutics | IOVA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/19/2026 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 12/18/2025 | argenx SE | ARGX | Downgrade | Neutral (Outperform) |
851.42 (717.80) |
-15.69% | Details | |
| 11/18/2025 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2025 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2025 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/3/2025 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2025 | Climb Bio | CLYM | New Coverage | Outperform (N/A) |
1.63 (7.18) |
340.49% | Details | |
| 8/6/2025 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/18/2025 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2025 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/25/2025 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2025 | Enliven Therapeutics | ELVN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2025 | Agenus Inc. | AGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/13/2025 | Agenus Inc. | AGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2025 | Iovanace Biotherapeutics | IOVA | Downgrade | Neutral (Outperform) |
3.13 (5.13) |
63.9% | Details | |
| 5/8/2025 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/12/2025 | Agenus Inc. | AGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2025 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 12/5/2024 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2024 | Spyre | SYRE | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/3/2024 | Ocular Therapeutix | OCUL | Maintain | Outperform (Outperform) |
|
Details | ||
| 11/15/2024 | Enliven Therapeutics | ELVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2024 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2024 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2024 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2024 | Spyre | SYRE | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/23/2024 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/16/2024 | Coherus Biosciences | CHRS | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/12/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/10/2024 | Nuvalent | NUVL | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/5/2024 | Cogent | COGT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/14/2024 | Mersana | MRSN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2024 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2024 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/19/2024 | Agenus Inc. | AGEN | Downgrade | Neutral (Outperform) |
17.73 (2.95) |
-83.36% | Details | |
| 7/1/2024 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2024 | Enliven Therapeutics | ELVN | New Coverage | Outperform (N/A) |
20.94 (29.44) |
40.59% | Details | |
| 5/10/2024 | Mersana | MRSN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/2/2024 | Spyre | SYRE | New Coverage | Outperform (N/A) |
33.03 (40.15) |
21.56% | Details | |
| 4/17/2024 | Agenus Inc. | AGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/29/2024 | Mersana | MRSN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2024 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2024 | Cogent | COGT | Downgrade | Neutral (Outperform) |
8.95 (37.08) |
314.3% | Details | |
| 2/23/2024 | Nuvalent | NUVL | New Coverage | Outperform (N/A) |
82.53 (99.41) |
20.45% | Details | |
| 2/20/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/23/2024 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2024 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2023 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2023 | Coherus Biosciences | CHRS | New Coverage | Outperform (N/A) |
1.80 (1.82) |
1.11% | Details | |
| 11/8/2023 | Agenus Inc. | AGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2023 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2023 | Harpoon Therapeutics | HARP | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2023 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2023 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/28/2023 | Mersana | MRSN | Downgrade | Neutral (Outperform) |
3.91 (29.08) |
643.73% | Details | |
| 7/17/2023 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/20/2023 | Surface Oncology | SURF | Downgrade | Neutral (Outperform) |
0.74 (1.07) |
44.59% | Details | |
| 6/6/2023 | Agenus Inc. | AGEN | New Coverage | Outperform (N/A) |
1.60 (17.73) |
1008.13% | Details | |
| 5/23/2023 | Iovanace Biotherapeutics | IOVA | Maintain | (Outperform) |
|
Details | ||
| 5/10/2023 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2023 | Iveric Bio | ISEE | Downgrade | Neutral (Outperform) |
37.72 (39.95) |
5.91% | Details | |
| 5/1/2023 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/21/2023 | Ocular Therapeutix | OCUL | New Coverage | Outperform (N/A) |
5.82 (10.27) |
76.46% | Details | |
| 2/21/2023 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Harpoon Therapeutics | HARP | Downgrade | Neutral (Outperform) |
0.82 (23.01) |
2706.1% | Details | |
| 4/7/2022 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Iveric Bio | ISEE | New Coverage | Outperform (N/A) |
16.10 (39.95) |
148.14% | Details | |
| 2/25/2022 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2021 | SAB Biotherapeutics | SABS | New Coverage | Outperform (N/A) |
7.91 (3.79) |
-52.09% | Details |
